Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-71

Trump and RFK Jr doing a number on the FDA at the moment. The decline in tech stocks has tapered but biotech getting hammered. The NBI and Acadia both down heavily overnight so the macro environment is terrible right now . Of course barring Neuren announcing their Type C meeting has been delayed then this shouldn't affect them at all but the market rarely seems to care. I expect the sell pressure on Neuren to continue and therefore the buying opportunity. Financially Neuren has all it needs to prosecute its plans for 2591 and if successful there is no way the share price will not be significantly higher than where we are now.